Arrowhead’s Plozasiran Projected to Surpass $700M in Sales by 2032, Addressing Major Unmet Needs in Dyslipidemia Treatment

- GlobalData reports that Arrowhead Pharmaceuticals' plozasiran is forecasted to launch in 2026 and could reach over $700 million in sales by 2032.
- Plozasiran is a siRNA therapeutic candidate that targets apolipoprotein C-III (APOC3) for the treatment of severe hypertriglyceridemia, mixed dyslipidemia, and familial chylomicronemia.
- Plozasiran has shown promising results in clinical trials, including significant reductions in triglycerides and multiple atherogenic lipoproteins in patients with SHTG, FCS, and mixed dyslipidemia.
- The drug has been granted fast-track designation by the FDA for the significant reduction in triglycerides in adult patients with familial chylomicronemia syndrome (FCS).
- According to GlobalData, there is a significant unmet need for drugs that treat severe genetic disorders, including FCS and familial hypercholesterolemia, as there are currently no FDA-approved therapies to treat FCS.
- Plozasiran is also expected to address the unmet need for patients with SHTG, who have limited treatment options.
- Plozasiran is being developed based on Arrowhead's targeted RNAi molecule (TRiM) platform.